| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of mycosis fungoides with large cell transformation following dupilumab treatment
|
Poyner, E.
|
|
2019
|
119 |
S1 |
p. S42-S43
|
artikel
|
| 2 |
A diagnostic two gene classifier in patients with mycosis fungoides: a retrospective multicenter study
|
Nielsen, P.R.
|
|
2019
|
119 |
S1 |
p. S11
|
artikel
|
| 3 |
Allogeneic hematopoietic stem cell transplantation for the treatment of patients with refractory mycosis fungoides/Sezary syndrome: a single center experience
|
Papadavid, E.
|
|
2019
|
119 |
S1 |
p. S34
|
artikel
|
| 4 |
Altered expression of inflammasome on the skin and lymph nodes in Sézary syndrome
|
Manfrere, K.C.G.
|
|
2019
|
119 |
S1 |
p. S21
|
artikel
|
| 5 |
A malignant PLCG1-PRKCQ-STAT3 signalin g axis controlling tumorigenesis and progression of cutaneous T-cell lymphomas
|
García-Díaz, N.
|
|
2019
|
119 |
S1 |
p. S6-S7
|
artikel
|
| 6 |
A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study
|
Stadler, R.
|
|
2019
|
119 |
S1 |
p. S32
|
artikel
|
| 7 |
Analysis of Sézary syndrome (SS) and lymphocytic variant of hypereosinophilic syndrome (L-HES) transcriptome identify common genes to reflect similar manifestation and highlight genes important in proliferation
|
Moerman-Herzog, Andrea
|
|
2019
|
119 |
S1 |
p. S5
|
artikel
|
| 8 |
An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review
|
Gru, Alejandro A.
|
|
2019
|
119 |
S1 |
p. S26-S27
|
artikel
|
| 9 |
An overall response in skin is associated with improved HRQoL in patients with MF/SS enrolled in the PROCLIPI study
|
Molloy, K.
|
|
2019
|
119 |
S1 |
p. S38-S39
|
artikel
|
| 10 |
Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma
|
Lindahl, Lise M.
|
|
2019
|
119 |
S1 |
p. S5
|
artikel
|
| 11 |
Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+IFN-γ– NK cells and can be potentiated by interferon-α in cutaneous lymphoma
|
Kruglov, Oleg
|
|
2019
|
119 |
S1 |
p. S33
|
artikel
|
| 12 |
A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas
|
Maakaron, J.
|
|
2019
|
119 |
S1 |
p. S28
|
artikel
|
| 13 |
A retrospective analysis of patients with co-existent mycosis fungoides and primary cutaneous anaplastic large cell lymphoma from the Australian Cutaneous Lymphoma Network database
|
Gao, C.
|
|
2019
|
119 |
S1 |
p. S4
|
artikel
|
| 14 |
A review of 65 patients with mycosis fungoides/Sezary syndrome treated with extracorporeal photopheresis: our experience at Peter MacCallum Cancer Centre
|
Gao, C.
|
|
2019
|
119 |
S1 |
p. S29
|
artikel
|
| 15 |
Augmented apoptotic efficacy of brentuximab vedotin combined with lenalidomide in CD-30 expressing Sézary syndrome cell lines
|
Bakou, V.
|
|
2019
|
119 |
S1 |
p. S18-S19
|
artikel
|
| 16 |
Blastic plasmocytoid dendritic cell neoplasm: a series of fourteen cases from a reference center in Brazil
|
Cury-Martins, J.
|
|
2019
|
119 |
S1 |
p. S3
|
artikel
|
| 17 |
Blocking TNF-α/Th17 pathway with monoclonal cytokine antibodies may aggravate the course of mycosis fungoides: a multicenter retrospective analysis of real-world clinical data
|
Amitay-Laish, I.
|
|
2019
|
119 |
S1 |
p. S42
|
artikel
|
| 18 |
Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
|
Scarisbrick, Julia
|
|
2019
|
119 |
S1 |
p. S31
|
artikel
|
| 19 |
Cancer-associated fibroblasts: characterization and role in mycosis fungoides lesions
|
Moyal, L.
|
|
2019
|
119 |
S1 |
p. S12
|
artikel
|
| 20 |
CD30 and lymphomas: the clue for four?
|
Mangas, C.
|
|
2019
|
119 |
S1 |
p. S37
|
artikel
|
| 21 |
CD30 expression in rare cutaneous lymphomas
|
Wehkamp, Ulrike
|
|
2019
|
119 |
S1 |
p. S18
|
artikel
|
| 22 |
Cell adhesion molecule 1 (CADM1) can be a biomarker for Sézary syndrome
|
Nakagawa, Y.
|
|
2019
|
119 |
S1 |
p. S7
|
artikel
|
| 23 |
Challenges in the diagnosis of CD30+ anaplastic large-cell lymphoma
|
Dobos, G.
|
|
2019
|
119 |
S1 |
p. S24-S25
|
artikel
|
| 24 |
Chronic actinic dermatitis or cutaneous T cell lymphoma: a case report
|
Remenyik, E.
|
|
2019
|
119 |
S1 |
p. S44
|
artikel
|
| 25 |
Circulating tumor cells in mycosis fungoides patients detected by next generation sequencing of T-cell-receptor gene rearrangements and correlation with clinical stage
|
Pietzka, Sophie
|
|
2019
|
119 |
S1 |
p. S1
|
artikel
|
| 26 |
Clinical aspects and outcome of lymphoblastic leukemia/lymphoma with cutaneous involvement
|
Bontoux, C.
|
|
2019
|
119 |
S1 |
p. S10-S11
|
artikel
|
| 27 |
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicenter study
|
Brüggen, Marie-Charlotte
|
|
2019
|
119 |
S1 |
p. S33
|
artikel
|
| 28 |
Clinical, histological and molecular characteristics of ALK-positive primary cutaneous anaplastic large cell lymphoma
|
Melchers, R.C.
|
|
2019
|
119 |
S1 |
p. S18
|
artikel
|
| 29 |
Clinician-level variation in mechlorethamine treatment duration in mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
|
Querfeld, Christian
|
|
2019
|
119 |
S1 |
p. S8
|
artikel
|
| 30 |
Clonality assessment in blood and immunotyping of malignant cells to support choice of treatment for erythrodermic CTCL patients, a CD52 success story of precision medicine
|
Vieyra-Garcia, Pablo A.
|
|
2019
|
119 |
S1 |
p. S14
|
artikel
|
| 31 |
Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in France, Germany Italy, Spain and the United Kingdom
|
Illidge, T.
|
|
2019
|
119 |
S1 |
p. S36
|
artikel
|
| 32 |
Cutaneous lymphoid hyperplasia: clinical course and disease outcome in a case series
|
Georgiou, E.
|
|
2019
|
119 |
S1 |
p. S22
|
artikel
|
| 33 |
Cutaneous lymphomas behave worse in patients treated with biologics for psoriasis: a multicenter study
|
Nikolaou, Vassiliki
|
|
2019
|
119 |
S1 |
p. S41
|
artikel
|
| 34 |
Cutaneous T-cell lymphoma and second cancer: a two-center experience
|
Pileri, A.
|
|
2019
|
119 |
S1 |
p. S38
|
artikel
|
| 35 |
Cutaneous T-cell lymphoma cells release proapoptotic Fas ligand in lysosomal secretory vesicles
|
de Masson, Adèle
|
|
2019
|
119 |
S1 |
p. S17
|
artikel
|
| 36 |
Cutaneous T cell lymphoma mouse model used to study the therapeutic mechanisms of phototherapy
|
Vieyra-Garcia, Pablo A.
|
|
2019
|
119 |
S1 |
p. S14
|
artikel
|
| 37 |
Defining B2 involvement in Sezary syndrome results from the PROCLIPI study
|
Hunjan, Manrup
|
|
2019
|
119 |
S1 |
p. S6
|
artikel
|
| 38 |
Demodex-induced follicular mucinosis of the head and neck mimicking folliculotropic mycosis fungoides
|
Trager, M.H.
|
|
2019
|
119 |
S1 |
p. S10
|
artikel
|
| 39 |
Demyelinating motor neuropathy of the median nerve following brentuximab vedotin extravasate
|
Hoffmann, J.C.
|
|
2019
|
119 |
S1 |
p. S32-S33
|
artikel
|
| 40 |
Diagnostic and clinical significance of eccrinotropism in mycosis fungoides
|
Calzavara-Pinton, I.
|
|
2019
|
119 |
S1 |
p. S22
|
artikel
|
| 41 |
Double-hit and dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas
|
Menguy, Sarah
|
|
2019
|
119 |
S1 |
p. S20
|
artikel
|
| 42 |
Early-stage mycosis fungoides: incidence and differential survival
|
Maguire, A.
|
|
2019
|
119 |
S1 |
p. S35
|
artikel
|
| 43 |
Effect of extracorporeal photopheresis on antibody-dependent cellular cytotoxicity in patients with Sézary syndrome
|
Iselin, Christoph
|
|
2019
|
119 |
S1 |
p. S16
|
artikel
|
| 44 |
Effect of oral psoralen plus UV-A (PUVA) photochemotherapy on quality of life, anxiety and depression in patients with early-stage mycosis fungoides
|
Graier, T.
|
|
2019
|
119 |
S1 |
p. S39
|
artikel
|
| 45 |
Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study
|
Kim, E.J.
|
|
2019
|
119 |
S1 |
p. S39
|
artikel
|
| 46 |
Efficacy of chlormethine gel in patients with stage I–IIA mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): re-analysis of a randomized phase 2 study
|
Kim, E.J.
|
|
2019
|
119 |
S1 |
p. S30
|
artikel
|
| 47 |
Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides (MF): results from the MAVORIC study
|
Scarisbrick, J.
|
|
2019
|
119 |
S1 |
p. S31-S32
|
artikel
|
| 48 |
Evaluation of blood Sézary markers by means of correlation with apoptosis resistance and clonality
|
Schneider, Sven
|
|
2019
|
119 |
S1 |
p. S1-S2
|
artikel
|
| 49 |
Evaluation of hematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma using reduced conditioning regime with total skin electron beam, total nodal irradiation and anti-thymocyte globulin
|
Ritchie, Sebastian
|
|
2019
|
119 |
S1 |
p. S29-S30
|
artikel
|
| 50 |
Expression of programmed death-1 (PD-1) and its ligands in Sézary syndrome
|
Saulite, Ieva
|
|
2019
|
119 |
S1 |
p. S13
|
artikel
|
| 51 |
Extranodal NK/T cell lymphoma, nasal type in a Brazilian tertiary center
|
Sanches, J.A.
|
|
2019
|
119 |
S1 |
p. S2
|
artikel
|
| 52 |
Folliculotropic mycosis fungoides in the setting of nivolumab immunotherapy
|
Nikolaou, V.
|
|
2019
|
119 |
S1 |
p. S44
|
artikel
|
| 53 |
Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study
|
Hodak, Emmilia
|
|
2019
|
119 |
S1 |
p. S27-S28
|
artikel
|
| 54 |
Generalized doxorubicin-induced radiation recall dermatitis following total skin electron beam therapy
|
Lamoureux, C.
|
|
2019
|
119 |
S1 |
p. S37-S38
|
artikel
|
| 55 |
Genetic alterations in CD30-positive lymphoproliferations
|
Maurus, K.
|
|
2019
|
119 |
S1 |
p. S14-S15
|
artikel
|
| 56 |
HDACi resminostat causes a sustained reduction of the pruritus mediator IL-31 in CTCL cells
|
Streubel, G.
|
|
2019
|
119 |
S1 |
p. S38
|
artikel
|
| 57 |
Health-related quality-of-life assessment in patients with cutaneous t-cell lymphoma and multimodality therapy
|
Baquero, J.
|
|
2019
|
119 |
S1 |
p. S40
|
artikel
|
| 58 |
Histopathology of cutaneous infiltrates in patients with MDS
|
Rizvi, S.M.H.
|
|
2019
|
119 |
S1 |
p. S21-S22
|
artikel
|
| 59 |
Importance of circulating miRNAs in CTCL diagnosis
|
Saraki, Konstantina
|
|
2019
|
119 |
S1 |
p. S12
|
artikel
|
| 60 |
Indolent gamma delta positive indolent cutaneous T-cell lymphoma: two cases and review of the literature
|
Junkins-Hopkins, J.M.
|
|
2019
|
119 |
S1 |
p. S21
|
artikel
|
| 61 |
Infection with human T-cell lymphotropic virus type-1 in primary cutaneous lymphoma: should we be testing all patients?
|
Rooke, Bethanie
|
|
2019
|
119 |
S1 |
p. S24
|
artikel
|
| 62 |
Interleukin 1 beta derived abscesses in a patient with folliculotropic and granulomatous mycosis fungoides with large cell transformation
|
Di Raimondo, C.
|
|
2019
|
119 |
S1 |
p. S15
|
artikel
|
| 63 |
In vitro effect of Jak and HDAC inhibitors in cutaneous T-cell lymphoma
|
Karagianni, F.
|
|
2019
|
119 |
S1 |
p. S4
|
artikel
|
| 64 |
Large cells with CD30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases
|
Prieto-Torres, Lucía
|
|
2019
|
119 |
S1 |
p. S23
|
artikel
|
| 65 |
Long-term clinical outcome and HAVCR2 mutations in 70 patients with subcutaneous panniculitis-like T-cell lymphoma: a study from the French Cutaneous Lymphoma Group
|
Sonigo, G.
|
|
2019
|
119 |
S1 |
p. S7-S8
|
artikel
|
| 66 |
Long-term disease control after stem cell transplantation in primary cutaneous T-cell lymphoma; a single-center analysis
|
Dimitriou, F.
|
|
2019
|
119 |
S1 |
p. S35
|
artikel
|
| 67 |
Low-dose gemcitabine therapy in CTCL: ‘real-life” data of the German Cutaneous Lymphoma Network
|
Blazejak, C.
|
|
2019
|
119 |
S1 |
p. S30-S31
|
artikel
|
| 68 |
Lymph node imaging and correlation with histological N-class: results from the PROCLIPI study show sum of the product of dimensions is the better predictor than single axis measurements
|
Yoo, J.
|
|
2019
|
119 |
S1 |
p. S25
|
artikel
|
| 69 |
Lymphomatoid papulosis type E with subcutaneous tissue infiltration and prominent rimming
|
Climent, F.
|
|
2019
|
119 |
S1 |
p. S22
|
artikel
|
| 70 |
Lymphomatoid papulosis types D and E: a multicentric series on 21 patients
|
Bergqvist, Christina
|
|
2019
|
119 |
S1 |
p. S19
|
artikel
|
| 71 |
Lymphoproliferative diseases among patients treated with biologicals: a case study and single center survey
|
Szakonyi, J.
|
|
2019
|
119 |
S1 |
p. S44
|
artikel
|
| 72 |
Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL
|
Roelens, M.
|
|
2019
|
119 |
S1 |
p. S4-S5
|
artikel
|
| 73 |
Metabolite profile of extracellular vesicles derived of a cutaneous T-cell lymphoma (CTCL) cell line
|
Palviainen, Mari
|
|
2019
|
119 |
S1 |
p. S16-S17
|
artikel
|
| 74 |
Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type at diagnosis and relapse
|
Schrader, Anne M.R.
|
|
2019
|
119 |
S1 |
p. S8-S9
|
artikel
|
| 75 |
Mycosis fungoides and variants of mycosis fungoides: a retrospective study of 93 patients in a Chinese population at a single center
|
Luo, Y.
|
|
2019
|
119 |
S1 |
p. S35
|
artikel
|
| 76 |
Mycosis fungoides is associated with melanoma in Israeli patients
|
Sherman, S.
|
|
2019
|
119 |
S1 |
p. S9-S10
|
artikel
|
| 77 |
Mycosis fungoides progression in the setting of ustekinumab therapy for psoriasis: report of two cases
|
Nikolaou, V.
|
|
2019
|
119 |
S1 |
p. S42
|
artikel
|
| 78 |
Mycosis fungoides: the great mimicker
|
Papathemeli, D.
|
|
2019
|
119 |
S1 |
p. S15
|
artikel
|
| 79 |
Neglected cases and quality of life
|
Makopoulou, A.M.
|
|
2019
|
119 |
S1 |
p. S40
|
artikel
|
| 80 |
N3 status in mycosis fungoides and Sézary syndrome is associated with a poor prognosis at first diagnosis and disease progression
|
Rooke, Bethanie
|
|
2019
|
119 |
S1 |
p. S21
|
artikel
|
| 81 |
Outcomes and prognostic factors in African American/black patients with mycosis fungoides and Sézary syndrome
|
Geller, S.
|
|
2019
|
119 |
S1 |
p. S9
|
artikel
|
| 82 |
PD-L1 is regulated by proinflammatory cytokines in cutaneous T cell lymphoma
|
Kil, Sung Hee
|
|
2019
|
119 |
S1 |
p. S41
|
artikel
|
| 83 |
PD-1 overexpression in Sézary syndrome is epigenetically regulated
|
Najidh, S.
|
|
2019
|
119 |
S1 |
p. S2
|
artikel
|
| 84 |
Pediatric lymphomatoid papulosis
|
Calzado-Villarreal, Leticia
|
|
2019
|
119 |
S1 |
p. S24
|
artikel
|
| 85 |
Pembrolizumab maintenance therapy after total-skin electron beam therapy (TSEBT) at erythrodermic mycosis fungoides patient
|
Christolouka, M.
|
|
2019
|
119 |
S1 |
p. S38
|
artikel
|
| 86 |
Peripheral T cell lymphoma, not otherwise specified involving the skin: is it always aggressive?
|
Cury-Martins, J.
|
|
2019
|
119 |
S1 |
p. S3-S4
|
artikel
|
| 87 |
Pityriasis lichenoides in patients with mycosis fungoides: our experience
|
Pikou, O.
|
|
2019
|
119 |
S1 |
p. S17
|
artikel
|
| 88 |
Pityriasis lichenoides: relevance of the current classification?
|
Lupu, Jeremy
|
|
2019
|
119 |
S1 |
p. S19
|
artikel
|
| 89 |
Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases
|
Menguy, Sarah
|
|
2019
|
119 |
S1 |
p. S20
|
artikel
|
| 90 |
Primary cutaneous lymphoma patterns in the north-western region of Romania
|
Fetica, B.
|
|
2019
|
119 |
S1 |
p. S23
|
artikel
|
| 91 |
Primary cutaneous marginal zone lymphoma: relevance of searching for a blood B-cell clone?
|
Legrand, A.
|
|
2019
|
119 |
S1 |
p. S13-S14
|
artikel
|
| 92 |
Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a comparative clinicopathological analysis of 5 cases
|
Castagna, J.
|
|
2019
|
119 |
S1 |
p. S23
|
artikel
|
| 93 |
Prognostic factors in mycosis fungoides: the PROCLIPI study
|
Scarisbrick, Julia
|
|
2019
|
119 |
S1 |
p. S26
|
artikel
|
| 94 |
Prognostic value of histopathologic features in folliculotropic mycosis fungoides presenting with plaques
|
van Santen, S.
|
|
2019
|
119 |
S1 |
p. S18-S19
|
artikel
|
| 95 |
Quality of life in Greek patients with mycosis fungoides: a cross-sectional study
|
Georgiou, E.
|
|
2019
|
119 |
S1 |
p. S40
|
artikel
|
| 96 |
Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicenter European EORTC study
|
Papadavid, E.
|
|
2019
|
119 |
S1 |
p. S34-S35
|
artikel
|
| 97 |
Resminostat increases NK cell-mediated lysis of malignant cells beneficially affecting the function of opsonizing antibodies
|
Parnitzke, U.
|
|
2019
|
119 |
S1 |
p. S3
|
artikel
|
| 98 |
Response to topical corticosteroid monotherapy in mycosis fungoides
|
Kartan, S.
|
|
2019
|
119 |
S1 |
p. S30
|
artikel
|
| 99 |
Retrospective validation of prognostic markers and models in a cohort of 60 patients with lethal mycosis fungoides
|
Porkert, Stefanie
|
|
2019
|
119 |
S1 |
p. S28
|
artikel
|
| 100 |
Risk of cardiovascular events in patients with cutaneous T-cell lymphomas
|
Johnson, C.
|
|
2019
|
119 |
S1 |
p. S5-S6
|
artikel
|
| 101 |
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B cell lymphoma, leg type
|
Di Raimondo, C.
|
|
2019
|
119 |
S1 |
p. S43-S44
|
artikel
|
| 102 |
Selection of suitable cases for random skin biopsy for the diagnosis for intravascular large B cell lymphoma
|
Fujii, K.
|
|
2019
|
119 |
S1 |
p. S17
|
artikel
|
| 103 |
Selective inhibition of HDAC6 sensitizes CTCL to PI3K inhibitors
|
Bobrowicz, Malgorzata
|
|
2019
|
119 |
S1 |
p. S37
|
artikel
|
| 104 |
Sequential comprehensive molecular work-up of treatment-resistant mycosis fungoides with systemic dissemination during a 4-year period
|
Wobser, M.
|
|
2019
|
119 |
S1 |
p. S16
|
artikel
|
| 105 |
Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma
|
Geskin, L.J.
|
|
2019
|
119 |
S1 |
p. S12
|
artikel
|
| 106 |
Single-cell RNA sequencing with TCR repertoire profiling of mycosis fungoides
|
Murray, D.
|
|
2019
|
119 |
S1 |
p. S7
|
artikel
|
| 107 |
SOLAR: a phase 2, global, randomized, active comparator study to investigate the efficacy and safety of cobomarsen in subjects with mycosis fungoides (MF)
|
Scarisbrick, Julia
|
|
2019
|
119 |
S1 |
p. S32
|
artikel
|
| 108 |
Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas
|
Muniesa, C.
|
|
2019
|
119 |
S1 |
p. S36
|
artikel
|
| 109 |
T-cell receptor rearrangements in the skin and blood of patients in the PROCLIPI study: detection of clonal rearrangements in the skin (and blood) correlates with the B-class of MF and SS patients
|
Wehkamp, U.
|
|
2019
|
119 |
S1 |
p. S25
|
artikel
|
| 110 |
The combination of brentuximab vedotin with skin-directed therapies in response to PD extend the time to the next therapeutic line
|
Stranzenbach, R.
|
|
2019
|
119 |
S1 |
p. S33
|
artikel
|
| 111 |
The diagnostic and prognostic value of five blood markers in cutaneous T-cell lymphomas: a validation cohort
|
Dobos, G.
|
|
2019
|
119 |
S1 |
p. S13
|
artikel
|
| 112 |
The expression of CD39 on circulating Sezary cells is genetically controlled
|
Picozza, M.
|
|
2019
|
119 |
S1 |
p. S43
|
artikel
|
| 113 |
The role of the extracellular matrix in promoting early stage mycosis fungoides
|
Ringe, John
|
|
2019
|
119 |
S1 |
p. S2-S3
|
artikel
|
| 114 |
Three cases of new diagnosis of mycosis fungoides following commencement on biologic therapies for presumed psoriasis/eczema
|
Yoo, J.
|
|
2019
|
119 |
S1 |
p. S41
|
artikel
|
| 115 |
Title Page
|
|
|
2019
|
119 |
S1 |
p. i
|
artikel
|
| 116 |
Transcriptional impact of resminostat and other HDAC inhibitors on disease-related gene expression in CTCL
|
Bretz, A.C.
|
|
2019
|
119 |
S1 |
p. S10
|
artikel
|
| 117 |
Transformed mycosis fungoides in a Brazilian tertiary center
|
Miyashiro, D.
|
|
2019
|
119 |
S1 |
p. S2
|
artikel
|
| 118 |
Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIPI) study
|
Quaglino, Pietro
|
|
2019
|
119 |
S1 |
p. S27
|
artikel
|
| 119 |
Treatment of mycosis fungoides/Sezary syndrome with brentuximab vedotin on the compassionate use program and CDF: outcomes and toxicities
|
Enefer, S.
|
|
2019
|
119 |
S1 |
p. S29
|
artikel
|
| 120 |
Treatment of rare patients with a primary cutaneous CD30+ lymphoproliferation developing extracutaneous disease: a retrospective study of 43 patients
|
Melchers, R.C.
|
|
2019
|
119 |
S1 |
p. S28-S29
|
artikel
|
| 121 |
Treatment of Sézary syndrome with alemtuzumab: a case series (2009–2019)
|
Fernandes, I.
|
|
2019
|
119 |
S1 |
p. S36-S37
|
artikel
|
| 122 |
Upregulation of HLA I on tumor skin T lymphocytes as a tumor immune escape mechanism in CTCL
|
Chang, Y.T.
|
|
2019
|
119 |
S1 |
p. S15-S16
|
artikel
|
| 123 |
Upregulation of integrin-associated protein on tumor T cells in CTCL inhibits IL-12 and Th1 immunity
|
Ignatova, Desislava
|
|
2019
|
119 |
S1 |
p. S13
|
artikel
|
| 124 |
Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm
|
Bastidas Torres, A.N.
|
|
2019
|
119 |
S1 |
p. S9
|
artikel
|
Tijdschrift beschrijving